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Background: Aging is known to play a key role in the development of cardiovascular diseases (CVDs).
Although aging is associated with mitochondria dysfunction, the impact of mitochondria-related aging
on CVDs has remained unclear in Taiwan.
Methods: The Mitochondria-AGing in NorthErn Taiwan (MAGNET) study, a prospective study, was initi-
ated in December 2010 to investigate the prevalence, determinants and the progress of CVDs and related
risks in a community-dwelling sample of about 3000 men and women from suburban areas of northern
Taiwan. The middle-aged population comprises the majority of the whole cohort in a 3-year collection
period. This study also examines a link between baseline characteristics and the development of
subclinical atherosclerosis. Data obtained will include information regarding baseline demographics,
body surface electrocardiography, blood bio-specimen components, measurement of cardiac and carotid
structure and function by ultrasonography, socioeconomic status, life styles, and life quality scoring
including short-form SF-36. Additional survey of blood samples, including analysis of endothelial
progenitor cells and the mitochondria function, and biomarkers, for a nested case-control study will be
performed. All participants will be followed for incidence and characterization of related cardiovascular
events.
Conclusion: This study is expected to clarify the role of mitochondria-related aging in the development of
CVDs and functional changes in sub-urban areas of Taiwan.
Copyright  2012, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Aging, or “senescence”, is a syndrome of changes with
a progressive decline in the functional maintenance of organ and
tissue homeostasis leading to an increasing propensity to several
degenerative disorders and eventual irreversible loss of viability
and even death1. Diseases related to the elderly population, such as
osteoporosis and cardiovascular diseases (CVDs), are usually
indistinguishable from aging per se2. Aging is multi-factorial and
could be genetically determined and further modiﬁed by the
environment3. One characteristic of aging is the association withof Medicine, Mackay Medical
District, New Taipei 25245,
.
iwan Society of Geriatric Emergenfunctional respiratory chain decline by enhanced production of
reactive oxygen species (ROS) and damage of mitochondria4,5.
Moreover, with altered activities of free radical-scavenging
enzymes in the aging process, oxidative stress in aging tissues
increases and can result in cell death or elicit apoptosis by induc-
tion of mitochondrial release of apoptogenic factors such as
cytochrome c6,7.
Aging is a major contributing factor to clinical CVDs8,9.
Atherosclerosis and impaired endothelial function, a precursor to
the chain of several CVDs, had been clearly established as being
associated with aging8e10. Functional declines in endogenous
vascular repair mechanisms [such as those mediated via endo-
thelial progenitor cells (EPCs)] linked to mitochondrial-associated
pro-apoptotic proteins had been proposed to partly explain this
phenomenon11,12.
On the one hand, metabolic abnormalities together with inci-
dence of diabetes mellitus (DM) had been observed to becy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Participants in MAGNET study and the follow-up period or serial evaluations over
extended timelines.
Stage Criteria
First stage 1. Residents of the 5 districts nearby the
Tamsui Mackay Memorial Hospital
2. Age at enrollment: 40e74 years
3. Complete a structured-questionnaire
4. Willing to provide 25 mL blood samples for
basic health examinations
Second stage Necessary:
1. Free of stroke or myocardial infarction
2. Willing to provide 25 mL blood samples
3. Willing to accept follow-up contacts and health examination
Optional (either one):
1. Higher risk of cardiovascular incident or osteoporosis.
2. Lower risk of cardiovascular incident or osteoporosis.
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a function to age had been linked to mitochondria dysfunction16e18
which can be accompanied by higher incidence of diabetes19,20
metabolic abnormalities21e23 and several unfavorable atheroscle-
rosis process24. On the other hand, remodeling of vascular and
cardiac structures with the aging process has been shown to be the
most important pathophysiologic determinant of elevated systolic
blood pressure, pulse pressure, and stroke25e28.
Although several pathways and individual components have
been reported to participate or contribute to the aging-related
clinical manifestations and pathophysiologies, a more compre-
hensive understanding among these background factors and the
potential interaction in-between them would clarify the exact
mechanisms underlying the pathogenesis of functional decline
with aging. Moreover, the link of such studies to clinical measures
and outcomes would build up a model between genotypes, cellular
dysfunction to risk factors modiﬁcation, and overt phenotypic
disease patterns - either signs or symptoms, presentation and
clinical end-points.
Measuring subclinical or “occult” disease before its overt clinical
onset or manifestations by using advanced non-invasive imaging
tools (suchasmyocardialdiastolic functionordeformation)oramore
sophisticated estimate (such as EPC ormitochondria function) is thus
novel in identifying and strengthening an earlier link between CVD
risks and future targets of events based on primary preventive
medicine.Aconstellationof suchcontinuousmeasureswould further
enhance the power of disclosing the subclinical abnormalities that
may not be identiﬁed by conventional measures.
This article describes the rationale and design of the
Mitochondria-AGing in NorthErn Taiwan (MAGNET) study. Con-
ducting this study will improve the understanding and gain further
insights into the mechanisms regarding the initiation and progress
with aging of several clinical aspects, physical conditions and
ﬁndings. In particular, wewill focus more on how the aging process
regulates cellular indices of EPC, functional integrity of mitochon-
dria, and the progression of atherosclerosis or associated changes in
cardiovascular systems and several related clinical disorders.
2. Materials and methods
2.1. Study objectives
The major objectives of MAGNET are: (1) to setup a community-
based cohort for the researches on aging-related disorders and to
determine the characteristics of age-related development and
progression of clinical frailty, disability (including psychosocial
components) and CVDs; (2) to determine the prevalence rate of
age-related subclinical frailty, disability with and without chronic
conditions, subclinical atherosclerosis and CVDs; (3) to assess age
and sex-related differences in subclinical frailty, disability and
CVDs, subclinical atherosclerosis and the progression, and incident
rates of future clinical overt CVDs; (4) to determine the impact and
utilization of newly identiﬁed markers or data and bio-specimen
for the other component projects associated with subclinical
diseases with or without chronicity and, to determinewhether they
may add further incremental predictive value over conventional
risk factors; and thus (5) to develop new methods or candidates
suitable for future screening purpose in a large-scaled population
and interventions, for characterizing risk among asymptomatic
persons; (6) to compare the quality of life of participants with and
without chronic conditions; and ﬁnally (7) to explore the associa-
tions between circulating EPC number, EPC/mitochondrial DNA
(mtDNA) haplotypes or variants and carotid artery elasticity/stiff-
ness, subclinical atherosclerosis, as well as cardiac structures and
functions.2.2. Recruitment of participants
Participants in the MAGNET study, followed periodically with
serial evaluations over extended timelines (Table 1), will include
3000 volunteer men and women, in as equal numbers as possible,
aging from 40e74 years from ﬁve different domestic districts in
New Taipei city with predominantly Chinese ethnic race (above
90%). At each site, approximately 500 eligible participants will be
recruited, with equal numbers of men and women gender as
possible, according to speciﬁed age proportions (Table 2).2.3. Visit and baseline examination
A study team composed of 20 medical and nursing students, 5
senior technicians, 3 nurses, and 12 cardiologists was set up in this
study near Sanzhi District or in the examination room speciﬁcally
designed for Mackay Medical College. A well-informed invitation
letter describing the objective and protocols of this study was sent
by mail to potential participants. In the ﬁrst examination, which
began in December 2010 (2010 Decembere2013 July), we use at
least two stages of health screening to enroll study participants
(Table 2). In the ﬁrst stage of health screening, we employ two
measures to promote the participation of the residents who are
40e74 years of age. We use structured questionnaire interviews to
obtain participants’ information associated with socio-
demographic characteristics, personal histories of illness and
medication, family histories of major illnesses, personal health
behavior and dietary patterns, health-related quality of life (SF-36),
and sleep quality (Table 3). Blood and urine samples will be
collected and assayed for the metabolic syndrome (MetS) compo-
nent risk factors. Selected samples will be analyzed for the amount
and function of EPC. The ﬁrst examination conducted over
a 12-month period, is designed to be the most comprehensive with
all detailed information collected. In the second stage of health
screening, we will use a case-control design coupling with
frequency matching to recruit participants. Participants who have
two or more component risk factors of MetS will be enrolled in the
study group. The control group will enroll individuals without any
component risk factor of MetS. The matching variables include age
(40e54, 55e64, and 65e74 years of age), sex, and residential
township. The number of study subject will be greater than 300 in
both groups. During the second study period (August 2013eJuly
2016), we will conduct follow-up health examinations to identify
the incident cases of MetS, DM, atherosclerosis, and osteoporosis.
And bio-specimen and personal data, including health-related
quality of life, medication and sleep quality, of the cohort
members will be collected again. The whole sequence of the
Table 2
Baseline examination componentsa and survey of MAGNET study.
Area North coast of New Taipei City North coast of New Taipei City North coast of New Taipei City
n 661 1000e1200 1000e1200
Examinations Examination 1 Examination 2 Examination 3
Study Period 2010 Dece2013 Jul 2013 Auge2016 Jul 2016 Auge2019 Jul
Baseline demographic data, past history Yes (QN, major diseases) Yes (QN, major diseases) Yes (QN, major diseases)
Medication usage No þ/- No
Blood pressures Yes Yes Yes
Body surface Electrocardiography Yes Yes Yes
Anthropometric measures Yes Yes Yes
Physical activity Yes (QN) No Yes (QN)
Psychosocial status (SF-36) Yes (QN) No Yes (QN)
Socioeconomic status Yes (QN) No No
Plasma biochemical data Yes Yes Yes
Biomarkers hs-CRP, homocysteine hs-CRP, homocysteine hs-CRP, homocysteine
Spot urine analysis Yes Yes Yes
Diet assessment Yes Yes Yes
Life styles/habits Yes Yes Yes
Body fat composition analysis No Yes Yes
Carotid ultrasound Yes Yes Yes
Carotid artery ﬂow doppler Yes Yes Yes
Echocardiography Yes Yes Yes
Note: hs-CRP, high sensitive C-reactive protein; QN, questionnaire.
a Examination components and numbers of participants, particularly for examinations 2 and 3 are subject to change based on participants available.
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MetS, carotid atherosclerosis, or cardiovascular events and
matched healthy controls will be determined. The second (from
August 2013eJuly 2016) and third (August 2016eJuly 2019) stage
examinations conducted over 12-months each, will include repeat
studies of selected baseline examinations with several new
measurements that could not be included at baseline due to limited
facilities, equipment, and resource availability.
2.4. Examination components and standard protocols
Written informed consent will be obtained from all participants
upon their arrival at all study clinic/sites. A detailed timeline and
planned components of the study is listed in Table 2. Information is
gathered on structured questionnaires to ascertain data including
each participant’s communication, baseline demographics, tobacco
usage, passive smoke exposure, alcohol consumption, diet content,
medical records, personal histories of illness and medications used
or prescribed, personal health behavior and dietary patterns,
health-related quality of life, and sleep quality and related family
history were all gathered with life styles, exercise capacity and
physical activities were registered and semi-quantiﬁed by a scaling
system.
2.5. Anthropometric measurement
Body height, weight, waist and hip circumference will be
measured with the participant in standing position wearing indoor
clothes and no shoes. Blood pressure will be measured by well-Table 3
Elements and spectrums of structured questionnaires used in MAGNET study.
Domain Contains
Socio-demographic characteristics Personal and parental
Personal health behavior Habit, quantity, and fr
and drugs or medici
Dietary habits Consumption frequenc
fried foods, milk and
Personal and family histories
of major illnesses
Hypertension, DM, hea
hyperglycemic, arth
functional gastrointe
Health-related quality of life SF-36
Sleep quality Pittsburgh Sleep Qualitrained nurses in the morning after 10 minutes rest, three times
on the right upper arm in sitting position. The average of the three
measurements of systolic and diastolic blood pressure will be used
for analysis. Body fat composition will be analyzed by foot-to-foot
bioimpedence Tanita BC 418 MA Segmental Body Composition
Analyzer (Tanita, Japan).
2.6. Laboratory measurements and methods used in the MAGNET
study
At the ﬁrst stage of health examination, we will provide free-of-
charge assays of total cholesterol, HDL cholesterol, LDL cholesterol,
triglycerides, glucose, uric acid, ALT/AST, creatinine, HbA1c, insulin,
high-sensitive C-reactive protein and homocysteine for each
participant. Venous blood samples (total volume, 25 mL) will be
collected from each participant after at least 8 hours of fasting. One
spot urine specimen will be collected for the determination of
urinary protein and glucose. In addition, 12-lead surface electro-
cardiography recordings (Fukuda 503-S, etc.), echocardiographic
examination, carotid intima-media thickness and stiffness
measurement (GE Vingmed Ultrasound, Norway), and bone
mineral density (BMD) of the posterior-anterior lumbar spine will
be measured by ultrasonometer GE Achilles Express (Absolute
Medical Equipment, Garnerville NY, USA) are obtained.
2.7. Mitochondria functional surveillance from EPCs
The number of EPCs, deﬁned as CD34þ/KDRþ cells, will be
determined using ﬂow cytometry analysis. Levels of reactiveeducational levels, ethnicity, and personal and family monthly income
equency of cigarette smoking, alcohol drinking, betel-quid chewing, tea drinking,
nes that were not sold through regular local channels
ies of major food items, including meat, processed or pickled foods, seafood,
dairy products, vegetables, fruits, fast-food, etc., during the last 2 weeks
rt diseases, liver diseases, cancers, COPD, TB, asthma, hyperlipidemia,
ritis, fracture, atopy, gastroesophageal reﬂux disease (GERD),
stinal disorders (FGID; parts of the Rome III), etc.
ty Index (PSQI)
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dichlorodihydroﬂuorescein diacetate dye (DCFDA; Invitrogen, Sun-
nyvale CA, USA) to reﬂect the oxidative stress in the cells. The
calcium content in EPCs will be evaluated using Fluo-8 calcium
indicator (ABD Bioquest, Carlsbad CA, USA). The mitochondria
membrane potential in EPCs will be evaluated using JC-1 dye (Invi-
trogen) to reﬂect the mitochondria membrane potential in the cells
with the distributionpattern and content ofmitochondria evaluated
by mitochondrion-speciﬁc staining. Mitochondrial function will be
evaluated using Seahorse Bioscience XF24 extracellular ﬂux
analyzer (Bucher Biotec AG, Basel, Switzerland) to measure oxygen
consumption rate (OCR, pmol/min) and extracellular acidiﬁcation
rate (ECAR, mpH/min). Three mitochondrial inhibitors, oligomycin
(10 mM), CCCP (50 mM), and antimycin-A (5 mM) (all from Sigma, St.
Louis, MO, USA) will be used sequentially for ATP synthase inhibi-
tion, proton gradient uncoupling, and electron transport chain
inhibition, respectively. Finally, mitochondrial function will be
evaluated by cell ATP production (ATPAssay Kit, Roche, Mannheim,
Germany), the end product of mitochondrial oxidative respiration.
2.8. Study organization
A steering committee consisting of the initial and principle
investigators, academic representatives and leaders, physician
leaders who applied for the grant for the project or its design, and
those who conduct for the study. A chaired publication committee
of investigators will be responsible for project-related publications.
Data processing, safety and storage will be managed by the
academic leadership upon completion of this project.
3. Discussion
One particular dimension and focus in the MAGNET study is to
address aging-related cardiovascular risk factors exposures,
possible interactions, and subsequent clinical events, as several
metabolic abnormalities at the cellular and tissue levels associated
with aging process are closely linked to CVDs. Although the theo-
retical incidence of cardiovascular events in the MAGNET study
would be lower than the CCCC study starting in 1990 in the adja-
cent Chin-Shan community29, partly due to expanded medical
resource availability and interventions after the broad use of nationTable 4
Statistical power to test our hypotheses related to intima-media-thickness in the prevale
Cross-sectional survey: prevalence of cardiovascular disease risk factors estimated by
subgroups of different gender and age population
Sample size (n) Prevalence (%)
All Participants
Sex
Men 1200 7.80%
Women 1800 7.50%
Age
Young (<65 y/o) 2250 4.0%
Elderly (65 y/o) 750 18.5%
Outcomes survey: future incidence of cardiovascular disease risk factors estimated by
in subgroups of different gender and age population
Sample Size (n) 5-year incidence r
All Participants
Sex
Men 1200 8.0%
Women 1800 4.0%
Age
Young (<65 y/o) 2250 3.5%
Elderly (65 y/o) 750 15.0%
Note: given that the exposed proportion in the non-case group is 30%.wide health insurance and the improved concept of primary
prevention, we still anticipate a CVD incidence of nearly 8% in the
men and 3e5% in the women population (168 participants total),
deﬁned as fatal or nonfatal myocardial infarction, angina pectoris
and stroke over a 5-year follow up period. The cardiovascular event
rate was estimated to be close or slightly higher than the MESA
study, which began in 2000 in six USA communities30,31, owing to
the enrollment of the study sample was started after the matura-
tion of National Health Insurance, the availability and the wide
utilization of medical resources, and advances in the recent decade
in Taiwan. Even though there is an increasing higher prevalence of
hyperlipidemia in the Sanzhi community, from 10.8% in 1991 to
approximately 20% recently with a nearly doubled prevalence of
coronary artery disease in our preliminary survey compared to
Chin-Shan community (4.1%)29 and, a nearly 30% of metabolic
syndrome prevalence. The increment may be due to a transition
into a developed country of Taiwan society with higher dietary fat
consumption and also, a much lower prevalence of habitual exer-
cise style and potentially higher cardiovascular risks from our
initial survey in the Sanzhi community compared to Chin-Shan
study (nearly 60%) might lead to similarly high or even higher
cardiovascular morbidities and future CVDs events despite
a potential higher utility of medical approach and risk factor
alteration/modiﬁcation in the recent era. Compared with the NIS-
SIN Project, an age-speciﬁc, community-based cohort from
suburban city aiming at investigating the health status and related
factors in the coming longevity era in Japan, we had higher prev-
alence of CVDs32. With the baseline cross-sectional data, for an
alpha error of 5 percent, the study will have more than 95 percent
power to identify relations between risk factors with a CVD prev-
alence of nearly 8% in the whole cohort with an odds ratio of 1.5 or
greater, and also in predicting CVDs (Table 4).
In the MAGNET study, we will examine the effect of aging in
a wide spectrum of alterations in a community-based sample
including several analyses of clinical and laboratory proﬁles. Such
phenotypic presentation with aging will be supplemented further
and strengthened by cellular and genetic analysis. In particular, we
will examine such age-related systemic alterations associated with
clinical metabolic derangements, atherosclerosis, prevalent CVDs,
and several subclinical measures, which may cover several major
dimensions including ventricular-arterial function integrations innce and development of clinical cardiovascular events MAGNET study.
Framingham Score related to abnormal IMT in the MAGNET cohort and in
Odds ratio Statistical power (%)
2.0 >99%
2.0 >99%
2.0 >99%
2.0 >99%
Framingham Score related to abnormal IMT in the MAGNET cohort and
ate (%) Odds ratio Statistical power (%)
2 >99%
2 >99%
2.0 >99%
2.0 >99%
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clinical outcomes. Of note, a mixture of a small number of partici-
pants in the community with clinically unrecognized diseases or
currently at a pre-clinical stage would render both subcellular
estimate and subclinical measures powerful and signiﬁcant. And
therefore, as diagnostic and analytic modalities continue to evolve
both from basic laboratories and clinical tools, setting of clear
boundaries between conventional risk factors and overt clinical
diseases is becoming less meaningful33. Based on a preventive
medicine approach, intervention in a participants “at risk” at an
earlier stage would be more cost efﬁcient.
Therefore, the current study will provide important and
constructive information about the pathophysiology of subclinical
disease development and the transition and progression in deter-
mining ﬁnal clinical presentation in several aspects. Also, MAGNET is
so far the ﬁrst study conducted in a prospective design aiming at the
integration of aging-related mitochondria dysfunction associated
with the clinical presentation of metabolic derangements, clinical
functional disturbances and CVDs with outcomes follow-up. The
establishment of such a relation in MAGNET has therefore the
potential incomplementingcurrentunderstandingandknowledgeof
aging-related functional decay at the cellular level with a link speciﬁc
to several systems and provide further insights into the interactions
between genetic factors, cellular degradation, risk factors exposure,
and subclinical measures and overt disease entities allowing for new
preventive strategies or treatment approaches in the future.
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